EC Number   |
Application |
Reference |
|---|
   3.4.21.B41 | diagnostics |
elevated tumor tissue protein expression levels of kallikrein-related peptidases KLK10 and KLK11 are associated with a favorable prognosis in advanced high-grade serous ovarian cancer patients |
752430 |
| 3.4.21.B41 | diagnostics |
enzyme KLK10 is significantly associated with other prognostic markers in gastroesophageal junction adenocarcinoma and Barrett esophagus, including depth of invasion, indicating its potential as independent biomarker |
731898 |
| 3.4.21.B41 | diagnostics |
hypermethylated KLK10 is frequent in hepatocellular carcinoma and may be useful as marker for clinical application |
708585 |
| 3.4.21.B41 | diagnostics |
KLK10 methylation can be used as a biomarker for non-small cell lung cancer |
707999 |
| 3.4.21.B41 | diagnostics |
KLK10 overexpression correlates with poor prognosis in colorectal cancer, being associated with liver metastases, decreased disease-free, and overall survival. Negative correlation between KLK10 expression and tumor grade, indicating that these two parameters. KLK10 expression, assessed by immunohistochemistry, is an independent indicator of poor prognosis. Assessment of KLK10 can be incorporatedto a multi-molecular prognostic model to achieve better and more accurate assessment of disease prognosis are affected by independent mechanisms |
732959 |
| 3.4.21.B41 | diagnostics |
urinary KLK10 is a promising non-invasive biomarker for the inoperability and incurability of gastric cancer |
754961 |
| 3.4.21.B41 | medicine |
high status KLK10 expression is a significant factor for disease-free survival and overall survival of colorectal cancer patients. KLK10 gene expression may be used as a marker of unfavorable prognosis for colorectal cancer |
718439 |
| 3.4.21.B41 | medicine |
kallikrein 10 may serve as a biomarker for uterine serous papillary carcinoma |
667128 |
